echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > The latest data of Sibman dual-target CAR-T unveiled at ASCO's total remission rate reached...

    The latest data of Sibman dual-target CAR-T unveiled at ASCO's total remission rate reached...

    • Last Update: 2021-06-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Sibyman Biotechnology (CBMG) today announced the latest clinical application of a new CD19/CD20 dual-target CAR-T cell product C-CAR039 for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) Data


    About this research

    About this research

    C-CAR039 is a new type of second-generation 4-1BB dual-target CAR-T with an optimized dual-specific antigen-binding domain, which can act on both CD19 and CD20 dual targets, and can eliminate CD19 in vivo and in vitro /CD20 single positive or double positive tumor cells


    In the phase I clinical trials in China (NCT04317885, NCT04655677, NCT04696432, NCT04693676), a dose escalation and expansion study was conducted to evaluate the safety and effectiveness of C-CAR039 in patients with r/r B-NHL


    Key findings and results

    Key findings and results

    As of April 20, 2021, 34 patients have received 1.


    According to the ASTCT 2019 standard, cytokine release syndrome (CRS) and immune effector cell-related neurotoxicity syndrome (ICANS) are graded


    As of the cut-off date, with a median follow-up of 7 months, the best overall response rate was 92.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.